Literature DB >> 21141266

[Population analysis by area of health of changes in consumption, price and expenditure of cardiovascular drugs in eight autonomous communities, Spain, 2005].

Gabriel Sanfélix-Gimeno1, Salvador Peiró, Julián Librero, Mónica Ausejo-Segura, Carmen Suárez-Alemán, Teresa Molina-López, Celaya M Concepción, Eusebi Castaño-Riera.   

Abstract

BACKGROUND: Variability in cardiovascular drugs is of great interest because of its high population use, its high expenditure and the availability of strong evidence supporting its use. The aim of this study is to describe variation in dispensation, price and pharmaceutical expenditure for 11 subgroups of cardiovascular drugs by healthcare areas.
METHODS: This was a population study describing dispensation for 11 subgroups of cardiovascular drugs among healthcare areas in 2005. POPULATION: 93 healthcare areas of the 8 participant Autonomous Regions. ANALYSIS: Descriptive analysis of dispensation (Defined Daily Dose (DDD) per 1,000 pensioners and day (DDD/1000P/Day), average price (euros per DDD), pharmaceutical expenditure (euros per 100 pensioners) and standardized consumption ratios. Small-area variation analysis was used to analyze observed variability.
RESULTS: Consumption of cardiovascular drugs oscillated between 324 DDD/1000p/Day for drugs with action on the renin-angiotensin system, and 6.5 DDD/1000p/Day for anti-aldosterone diuretics. Variation in consumption for areas in the 5th and 95th percentiles went from 1.8 times (digitalics) to 17.2 times (flavonoids), although most of the groups showed an extremal quotient of around 5. Variation in average prices was lower than in consumption (1.1 times for doxazosin and 3.7 for flavonoids) and variations in pharmaceutical expenditure was similar to variation in consumption (from 2.0 timesfor digitalics to 13.0 times for flavonoids).
CONCLUSIONS: Major variations in the consumption of cardiovascular drugs between healthcare areas, together with discreet variations in price mean there are big differences in pharmaceutical expenditure from one population to another.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21141266

Source DB:  PubMed          Journal:  Rev Esp Salud Publica        ISSN: 1135-5727


  4 in total

1.  [Prevalence of multiple medication and cardiovascular risk in patients over 65 years].

Authors:  Teresa Molina López; María de la O Caraballo Camacho; Daniel Palma Morgado; Soledad López Rubio; Juan Carlos Domínguez Camacho; Juan Carlos Morales Serna
Journal:  Aten Primaria       Date:  2011-09-15       Impact factor: 1.137

Review 2.  Modern Extraction and Purification Techniques for Obtaining High Purity Food-Grade Bioactive Compounds and Value-Added Co-Products from Citrus Wastes.

Authors:  Neelima Mahato; Mukty Sinha; Kavita Sharma; Rakoti Koteswararao; Moo Hwan Cho
Journal:  Foods       Date:  2019-10-23

3.  Are prescribing doctors sensitive to the price that their patients have to pay in the Spanish National Health System?

Authors:  Beatriz González López-Valcárcel; Julián Librero; Gabriel Sanfélix-Gimeno; Salvador Peiró
Journal:  BMC Health Serv Res       Date:  2011-12-08       Impact factor: 2.655

4.  Co-prescription patterns of cardiovascular preventive treatments: a cross-sectional study in the Aragon worker' health study (Spain).

Authors:  Isabel Aguilar-Palacio; Sara Malo; MªJesús Lallana; Cristina Feja; Juan González; Belén Moreno-Franco; MªJosé Rabanaque
Journal:  BMJ Open       Date:  2019-04-14       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.